GlassScriptPhysician profile
Kim L Vanatta
NPI 1518491851
$1,935.79
in general payments reported to CMS, 2019-2025
18 companies · $873 in 2025
The $873 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.17 · 2020: $21.23 · 2021: $185 · 2022: $107 · 2023: $44.82 · 2024: $630 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586.12 | 2019-2025 | |
| Abbott Laboratories | $231.86 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $203.60 | 2024 | Farxiga |
| Pfizer INC. | $203.22 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.98 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $116.47 | 2019-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $105.32 | 2024-2025 | Rexulti |
| Daiichi Sankyo INC. | $99.80 | 2024-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $41.92 | 2025 | Gardasil 9, Capvaxive, Enflonsia |
| Medtronic, INC. | $28.23 | 2024 | Intellis Adaptivestim |
| Kyowa Kirin, INC. | $26.45 | 2025 | |
| Neurocrine Biosciences, INC. | $21.83 | 2025 | |
| Alk-Abello, INC | $20.56 | 2024 | Odactra, Ragwitek, Grastek |
| Ge Healthcare | $19.77 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.86 | 2023 | Ultomiris |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $14.10 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.13 | 2020 | |
| Phathom Pharmaceuticals, INC. | $6.57 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Vanatta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.